Evidence map›Paper›PMID 36341187›Full record

ArticleIJU case reports2022

A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab.

Hiroyuki Fukunaga, Kenta Sumii, Shun Kawamura, Masato Okuno, Isao Taguchi, Gaku Kawabata

Open access · goldAbstract readCase Reports
In one paragraph

Article in IJU case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. [Immune Checkpoint Inhibitors Related Cystoureteritis:
A Case Report and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023
    Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hiroyuki FukunagaDepartment of Urology Kansai Rosai Hospital Amagasaki-shi Japan.ORCID https://orcid.org/0000-0002-6111-0305
Kenta SumiiDepartment of Urology Kansai Rosai Hospital Amagasaki-shi Japan.
Shun KawamuraDepartment of Urology Kansai Rosai Hospital Amagasaki-shi Japan.
Masato OkunoDepartment of Urology Kansai Rosai Hospital Amagasaki-shi Japan.
Isao TaguchiDepartment of Urology Kansai Rosai Hospital Amagasaki-shi Japan.
Gaku KawabataDepartment of Urology Kansai Rosai Hospital Amagasaki-shi Japan.
Kansai Rosai Hospital · JPHirosaki Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune-related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. Case presentation: The patient was a 60-year-old man with primary lung cancer who was receiving long-term nivolumab therapy. He was referred to our department due to the sudden onset of glans penile pain and micturition pain. We suspected non-bacterial cystitis as an immune-related adverse event caused by nivolumab and were able to treat it by administering prednisolone. While his symptoms and findings on cystoscopy recurred during prednisolone therapy, we were able to treat him again by administering an additional dose of infliximab. Conclusion: A few reports have described cases of immune checkpoint inhibitor-induced cystitis for which prednisolone was effective. This report is the first to describe cystitis as a steroid-resistant immune-related adverse event.

Indexed as

cystitisimmune checkpoint inhibitorsimmune related adverse eventinfliximabsteroid‐resistant

Identifiers

PMID36341187
PMCPMC9626353
OpenAlexW4297174545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.